Rani Therapeutics Holdings (RANI) Long-Term Deferred Tax (2021 - 2024)
Rani Therapeutics Holdings (RANI) posted quarterly Long-Term Deferred Tax of $18.9 million for Q3 2024, up 0.53% year-over-year from $18.8 million in Q4 2023, and little changed quarter-over-quarter from $18.9 million in Q2 2024.
Rani Therapeutics Holdings (RANI) Long-Term Deferred Tax (2021 - 2024) Analysis & Trends
Rani Therapeutics Holdings' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $18.9 million for Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 18.90 Mn |
| Jun 30, 2024 | 18.90 Mn |
| Mar 31, 2024 | 18.90 Mn |
| Sep 30, 2023 | 18.80 Mn |
| Jun 30, 2023 | 18.70 Mn |
| Mar 31, 2023 | 18.70 Mn |
| Sep 30, 2022 | 18.00 Mn |
| Jun 30, 2022 | 18.30 Mn |
| Mar 31, 2022 | 17.40 Mn |
| Jun 30, 2021 | 3.41 Mn |